comparemela.com

Latest Breaking News On - Macrogenics company profile - Page 1 : comparemela.com

Frazier Life Sciences Management L P Acquires 598,500 Shares of MacroGenics, Inc (NASDAQ:MGNX)

Frazier Life Sciences Management L.P. boosted its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 33.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,401,704 shares of the biopharmaceutical company’s stock after purchasing an additional […]

MacroGenics (NASDAQ:MGNX) Now Covered by Analysts at B Riley

B. Riley initiated coverage on shares of MacroGenics (NASDAQ:MGNX – Free Report) in a research note published on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $25.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages also recently issued reports on MGNX. TD Cowen raised shares of […]

GSA Capital Partners LLP Purchases 96,760 Shares of MacroGenics, Inc (NASDAQ:MGNX)

GSA Capital Partners LLP increased its position in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 74.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 225,918 shares of the biopharmaceutical company’s stock after buying an additional 96,760 shares during the […]

MacroGenics, Inc (NASDAQ:MGNX) Receives $13 67 Average PT from Analysts

MacroGenics, Inc (NASDAQ:MGNX) Receives $13 67 Average PT from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

MacroGenics, Inc (NASDAQ:MGNX) Receives $13 67 Consensus Target Price from Brokerages

MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.